Bone minerals are the inorganic compounds of the bone tissue that helps in strengthening the bones with its plate and globular structures. These minerals are formed from carbonated hydroxyapatite. Bone minerals are dynamic in living beings, it is continuously reabsorbed and build anew in the bone remodelling process. Bone functions as storehouse of calcium, from which calcium is continuously withdrawn or stored as a part of homeostasis. Bone mineral metabolism is refers to the maintenance of sufficient concentration of inorganic ions in blood serum irrespective of muscle tissue metabolic activities. Hormones such as parathormone and calcitonin plays vital role in controlling the muscle metabolic activities, these hormones are regulated by neuroendocrine system and produced by parathyroid and thyroid glands in the neck. Malfunction of these glands result in to metabolic in equilibrium and crates the problems of bone mineral metabolism. Bone and mineral density metabolic disorders are abnormalities of bones, caused by calcium, phosphorous, magnesium and vitamin D aberrations leading to several reversible clinical disorders. These disorders are generally treatable if the underlining cause is addressed with corrective treatment methods. These disorders are caused due to genetic or metabolic malfunctions in the body.
Highlights
The global Bone and Mineral Metabolism Disorders Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global bone and mineral metabolism disorders treatment market is undergoing market changes due to the higher competition among local and multinational players and this in turn helped to make treatment cost more economical. With the availability of wide variety of products in various forms and strengths in the bone and mineral metabolism disorders treatment market is expected to change the market dynamics over a given period of forecast. By disease type, sub segment such as osteoporosis and rickets in the global bone and mineral metabolism disorders treatment market are expected to grow in positive traction owing to increased prevalence of the diseases among the post-menopausal women and children in the various regions.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Bone and Mineral Metabolism Disorders Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bone and Mineral Metabolism Disorders Treatment.
The Bone and Mineral Metabolism Disorders Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Bone and Mineral Metabolism Disorders Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bone and Mineral Metabolism Disorders Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Merck
F. Hoffmann-La Roche
Novartis
Warner Chilcott
Sanofi
AbbVie
Amgen
Segment by Type
Bisphosphonates
Estrogens
Phosphate Binders
Non-Calcium, Non-Metal-Based Binder
Metal-Based Binders
Magnesium-Based Binders
Vitamin D Analogs and Supplements
Calcimimetic Agents
Calcium and Magnesium Supplements
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Drug Stores
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Bone and Mineral Metabolism Disorders Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Âé¶¹Ô´´ Analysis by Type
1.2.1 Global Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´ Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Bisphosphonates
1.2.3 Estrogens
1.2.4 Phosphate Binders
1.2.5 Non-Calcium, Non-Metal-Based Binder
1.2.6 Metal-Based Binders
1.2.7 Magnesium-Based Binders
1.2.8 Vitamin D Analogs and Supplements
1.2.9 Calcimimetic Agents
1.2.10 Calcium and Magnesium Supplements
1.3 Âé¶¹Ô´´ by Application
1.3.1 Global Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´ Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.3.5 Drug Stores
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´ Perspective (2018-2029)
2.2 Bone and Mineral Metabolism Disorders Treatment Growth Trends by Region
2.2.1 Global Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´ Size by Region: 2018 VS 2022 VS 2029
2.2.2 Bone and Mineral Metabolism Disorders Treatment Historic Âé¶¹Ô´´ Size by Region (2018-2023)
2.2.3 Bone and Mineral Metabolism Disorders Treatment Forecasted Âé¶¹Ô´´ Size by Region (2024-2029)
2.3 Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´ Dynamics
2.3.1 Bone and Mineral Metabolism Disorders Treatment Industry Trends
2.3.2 Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´ Drivers
2.3.3 Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´ Challenges
2.3.4 Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´ Restraints
3 Competition Landscape by Key Players
3.1 Global Top Bone and Mineral Metabolism Disorders Treatment Players by Revenue
3.1.1 Global Top Bone and Mineral Metabolism Disorders Treatment Players by Revenue (2018-2023)
3.1.2 Global Bone and Mineral Metabolism Disorders Treatment Revenue Âé¶¹Ô´´ Share by Players (2018-2023)
3.2 Global Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´ Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Bone and Mineral Metabolism Disorders Treatment Revenue
3.4 Global Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´ Concentration Ratio
3.4.1 Global Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´ Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Bone and Mineral Metabolism Disorders Treatment Revenue in 2022
3.5 Bone and Mineral Metabolism Disorders Treatment Key Players Head office and Area Served
3.6 Key Players Bone and Mineral Metabolism Disorders Treatment Product Solution and Service
3.7 Date of Enter into Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´
3.8 Mergers & Acquisitions, Expansion Plans
4 Bone and Mineral Metabolism Disorders Treatment Breakdown Data by Type
4.1 Global Bone and Mineral Metabolism Disorders Treatment Historic Âé¶¹Ô´´ Size by Type (2018-2023)
4.2 Global Bone and Mineral Metabolism Disorders Treatment Forecasted Âé¶¹Ô´´ Size by Type (2024-2029)
5 Bone and Mineral Metabolism Disorders Treatment Breakdown Data by Application
5.1 Global Bone and Mineral Metabolism Disorders Treatment Historic Âé¶¹Ô´´ Size by Application (2018-2023)
5.2 Global Bone and Mineral Metabolism Disorders Treatment Forecasted Âé¶¹Ô´´ Size by Application (2024-2029)
6 North America
6.1 North America Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´ Size (2018-2029)
6.2 North America Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´ Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´ Size by Country (2018-2023)
6.4 North America Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´ Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´ Size (2018-2029)
7.2 Europe Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´ Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´ Size by Country (2018-2023)
7.4 Europe Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´ Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´ Size (2018-2029)
8.2 Asia-Pacific Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´ Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´ Size by Region (2018-2023)
8.4 Asia-Pacific Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´ Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´ Size (2018-2029)
9.2 Latin America Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´ Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´ Size by Country (2018-2023)
9.4 Latin America Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´ Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´ Size (2018-2029)
10.2 Middle East & Africa Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´ Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´ Size by Country (2018-2023)
10.4 Middle East & Africa Bone and Mineral Metabolism Disorders Treatment Âé¶¹Ô´´ Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Detail
11.1.2 Merck Business Overview
11.1.3 Merck Bone and Mineral Metabolism Disorders Treatment Introduction
11.1.4 Merck Revenue in Bone and Mineral Metabolism Disorders Treatment Business (2018-2023)
11.1.5 Merck Recent Development
11.2 F. Hoffmann-La Roche
11.2.1 F. Hoffmann-La Roche Company Detail
11.2.2 F. Hoffmann-La Roche Business Overview
11.2.3 F. Hoffmann-La Roche Bone and Mineral Metabolism Disorders Treatment Introduction
11.2.4 F. Hoffmann-La Roche Revenue in Bone and Mineral Metabolism Disorders Treatment Business (2018-2023)
11.2.5 F. Hoffmann-La Roche Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Bone and Mineral Metabolism Disorders Treatment Introduction
11.3.4 Novartis Revenue in Bone and Mineral Metabolism Disorders Treatment Business (2018-2023)
11.3.5 Novartis Recent Development
11.4 Warner Chilcott
11.4.1 Warner Chilcott Company Detail
11.4.2 Warner Chilcott Business Overview
11.4.3 Warner Chilcott Bone and Mineral Metabolism Disorders Treatment Introduction
11.4.4 Warner Chilcott Revenue in Bone and Mineral Metabolism Disorders Treatment Business (2018-2023)
11.4.5 Warner Chilcott Recent Development
11.5 Sanofi
11.5.1 Sanofi Company Detail
11.5.2 Sanofi Business Overview
11.5.3 Sanofi Bone and Mineral Metabolism Disorders Treatment Introduction
11.5.4 Sanofi Revenue in Bone and Mineral Metabolism Disorders Treatment Business (2018-2023)
11.5.5 Sanofi Recent Development
11.6 AbbVie
11.6.1 AbbVie Company Detail
11.6.2 AbbVie Business Overview
11.6.3 AbbVie Bone and Mineral Metabolism Disorders Treatment Introduction
11.6.4 AbbVie Revenue in Bone and Mineral Metabolism Disorders Treatment Business (2018-2023)
11.6.5 AbbVie Recent Development
11.7 Amgen
11.7.1 Amgen Company Detail
11.7.2 Amgen Business Overview
11.7.3 Amgen Bone and Mineral Metabolism Disorders Treatment Introduction
11.7.4 Amgen Revenue in Bone and Mineral Metabolism Disorders Treatment Business (2018-2023)
11.7.5 Amgen Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Merck
F. Hoffmann-La Roche
Novartis
Warner Chilcott
Sanofi
AbbVie
Amgen
Ìý
Ìý
*If Applicable.